{"transactions":[{"id":831202,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Series B  Convertible Preferred Stock","published_at":"2026-03-23T20:03:44.000Z","date":"2026-03-20","kind":"exercise","planned":false,"acquired":false,"shares":50,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Convertible Non-Redeemable Preferred Stock (\"Series B Preferred Stock\") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the \"Certificate of Designations\") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a \"Security\"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Convertible Non-Redeemable Preferred Stock (\"Series B Preferred Stock\") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the \"Certificate of Designations\") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a \"Security\"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Convertible Non-Redeemable Preferred Stock (\"Series B Preferred Stock\") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the \"Certificate of Designations\") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a \"Security\"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Convertible Non-Redeemable Preferred Stock (\"Series B Preferred Stock\") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the \"Certificate of Designations\") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a \"Security\"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":66667},"source":{"system":"sec-edgar","filing":"0001108205-26-000039","document":"wk-form4_1774296221.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820526000039/wk-form4_1774296221.xml","form_type":"4"}},{"id":831201,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2026-03-23T20:03:44.000Z","date":"2026-03-20","kind":"exercise","planned":false,"acquired":true,"shares":66667,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Convertible Non-Redeemable Preferred Stock (\"Series B Preferred Stock\") automatically converted into 1,333.33 shares of Common Stock, for no additional consideration, at 5 p. m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the \"Certificate of Designations\") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations). Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a \"Security\"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person."}],"balance_after":66667,"source":{"system":"sec-edgar","filing":"0001108205-26-000039","document":"wk-form4_1774296221.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820526000039/wk-form4_1774296221.xml","form_type":"4"}},{"id":835516,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Series C Warrant (right to buy)","published_at":"2026-03-18T20:21:54.000Z","date":"2026-03-17","kind":"grant","planned":false,"acquired":true,"shares":66667,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a \"Security\"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Series C Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing on March 17, 2026."}],"balance_after":66667,"derivative":{"exercise_price":0.75,"expiration_date":"2027-07-08","underlying":"Common Stock","underlying_shares":66667},"source":{"system":"sec-edgar","filing":"0001108205-26-000027","document":"wk-form4_1773865309.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820526000027/wk-form4_1773865309.xml","form_type":"4"}},{"id":835515,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Series B Warrant (right to buy)","published_at":"2026-03-18T20:21:54.000Z","date":"2026-03-17","kind":"grant","planned":false,"acquired":true,"shares":66667,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series B Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series B Warrant) and will terminate upon the 30th calendar day following date on which the Company publicly announces that the fifth patient has been dosed in the Company's Phase 2 clinical trial of emavusertib in combination with an approved Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia (\"Initial Termination Date\"). If the closing sale price of the Company's Common Stock at the Initial Termination Date is below $0.75 (the \"Exercise Price\"), such Exercise Price will be reset to the closing sale price of the Company's Common Stock on the Initial Termination Date (provided that the Exercise Price will not be reduced to less than 50% of the initial Exercise Price) and the Initial Termination Date will be extended an additional 30 days."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a \"Security\"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series B Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series B Warrant) and will terminate upon the 30th calendar day following date on which the Company publicly announces that the fifth patient has been dosed in the Company's Phase 2 clinical trial of emavusertib in combination with an approved Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia (\"Initial Termination Date\"). If the closing sale price of the Company's Common Stock at the Initial Termination Date is below $0.75 (the \"Exercise Price\"), such Exercise Price will be reset to the closing sale price of the Company's Common Stock on the Initial Termination Date (provided that the Exercise Price will not be reduced to less than 50% of the initial Exercise Price) and the Initial Termination Date will be extended an additional 30 days."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series B Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series B Warrant) and will terminate upon the 30th calendar day following date on which the Company publicly announces that the fifth patient has been dosed in the Company's Phase 2 clinical trial of emavusertib in combination with an approved Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia (\"Initial Termination Date\"). If the closing sale price of the Company's Common Stock at the Initial Termination Date is below $0.75 (the \"Exercise Price\"), such Exercise Price will be reset to the closing sale price of the Company's Common Stock on the Initial Termination Date (provided that the Exercise Price will not be reduced to less than 50% of the initial Exercise Price) and the Initial Termination Date will be extended an additional 30 days."}],"balance_after":66667,"derivative":{"exercise_price":0.75,"underlying":"Common Stock","underlying_shares":66667},"source":{"system":"sec-edgar","filing":"0001108205-26-000027","document":"wk-form4_1773865309.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820526000027/wk-form4_1773865309.xml","form_type":"4"}},{"id":835514,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Series A Warrant (right to buy)","published_at":"2026-03-18T20:21:54.000Z","date":"2026-03-17","kind":"grant","planned":false,"acquired":true,"shares":66667,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a \"Security\"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each Series A Warrant became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series A Warrant) on March 17, 2026."}],"balance_after":66667,"derivative":{"exercise_price":0.75,"expiration_date":"2031-01-08","underlying":"Common Stock","underlying_shares":66667},"source":{"system":"sec-edgar","filing":"0001108205-26-000027","document":"wk-form4_1773865309.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820526000027/wk-form4_1773865309.xml","form_type":"4"}},{"id":835513,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Series B  Convertible Preferred Stock","published_at":"2026-03-18T20:21:54.000Z","date":"2026-03-17","kind":"grant","planned":false,"acquired":true,"shares":50,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Convertible Non-Redeemable Preferred Stock (\"Series B Preferred Stock\") automatically converts into 1,333.33 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the \"Certificate of Designations\") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a \"Security\"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Convertible Non-Redeemable Preferred Stock (\"Series B Preferred Stock\") automatically converts into 1,333.33 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the \"Certificate of Designations\") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Convertible Non-Redeemable Preferred Stock (\"Series B Preferred Stock\") automatically converts into 1,333.33 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the \"Certificate of Designations\") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations)."}],"balance_after":50,"derivative":{"underlying":"Common Stock","underlying_shares":66667},"source":{"system":"sec-edgar","filing":"0001108205-26-000027","document":"wk-form4_1773865309.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820526000027/wk-form4_1773865309.xml","form_type":"4"}},{"id":1159715,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Employee stock option (right to buy)","published_at":"2025-05-05T20:26:25.000Z","date":"2025-05-01","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":2.48,"value":496000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option vests over four years, with 25% of the original 200,000 shares underlying the award vesting on May 1, 2026 and an additional 6.25% of the original number of shares underlying the award vesting on each successive three-month period thereafter, subject to continued service."}],"balance_after":200000,"derivative":{"exercise_price":2.48,"expiration_date":"2035-04-30","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001108205-25-000042","document":"wk-form4_1746476779.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820525000042/wk-form4_1746476779.xml","form_type":"4"}},{"id":1433715,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-14T20:07:30.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":53254,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the \"Repriced Options\"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the \"Repricing\"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the \"Repriced Options\"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the \"Repricing\"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"One-third (1/3) vests on March 7, 2025, with the remainder vesting in twenty-four equal monthly installments thereafter."}],"balance_after":200000,"derivative":{"exercise_price":0.55,"expiration_date":"2034-03-06","underlying":"Common Stock","underlying_shares":53254},"source":{"system":"sec-edgar","filing":"0000950170-24-097328","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000095017024097328/ownership.xml","form_type":"4"}},{"id":1433714,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-14T20:07:30.000Z","date":"2024-08-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":53254,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the \"Repriced Options\"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the \"Repricing\"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the \"Repriced Options\"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the \"Repricing\"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"One-third (1/3) vests on March 7, 2025, with the remainder vesting in twenty-four equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":7.38,"expiration_date":"2034-03-06","underlying":"Common Stock","underlying_shares":53254},"source":{"system":"sec-edgar","filing":"0000950170-24-097328","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000095017024097328/ownership.xml","form_type":"4"}},{"id":1433713,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-14T20:07:30.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":146746,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the \"Repriced Options\"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the \"Repricing\"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the \"Repriced Options\"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the \"Repricing\"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"One-third (1/3) vests on March 7, 2025, with the remainder vesting in twenty-four equal monthly installments thereafter."}],"balance_after":146746,"derivative":{"exercise_price":0.55,"expiration_date":"2034-03-06","underlying":"Common Stock","underlying_shares":146746},"source":{"system":"sec-edgar","filing":"0000950170-24-097328","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000095017024097328/ownership.xml","form_type":"4"}},{"id":1433712,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-14T20:07:30.000Z","date":"2024-08-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":146746,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the \"Repriced Options\"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the \"Repricing\"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the \"Repriced Options\"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the \"Repricing\"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"One-third (1/3) vests on March 7, 2025, with the remainder vesting in twenty-four equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":7.38,"expiration_date":"2034-03-06","underlying":"Common Stock","underlying_shares":146746},"source":{"system":"sec-edgar","filing":"0000950170-24-097328","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000095017024097328/ownership.xml","form_type":"4"}},{"id":1433711,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-14T20:07:30.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the \"Repriced Options\"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the \"Repricing\"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the \"Repriced Options\"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the \"Repricing\"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Option vests in twenty-four equal monthly installments starting from February 15, 2023."}],"balance_after":90000,"derivative":{"exercise_price":0.55,"expiration_date":"2033-02-14","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0000950170-24-097328","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000095017024097328/ownership.xml","form_type":"4"}},{"id":1433710,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-14T20:07:30.000Z","date":"2024-08-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the \"Repriced Options\"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the \"Repricing\"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the \"Repriced Options\"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the \"Repricing\"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Option vests in twenty-four equal monthly installments starting from February 15, 2023."}],"balance_after":0,"derivative":{"exercise_price":1.17,"expiration_date":"2033-02-14","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0000950170-24-097328","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000095017024097328/ownership.xml","form_type":"4"}},{"id":1433709,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-14T20:07:30.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the \"Repriced Options\"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the \"Repricing\"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the \"Repriced Options\"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the \"Repricing\"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option vests in twenty-four equal monthly installments starting from November 15, 2022."}],"balance_after":60000,"derivative":{"exercise_price":0.55,"expiration_date":"2032-11-14","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-24-097328","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000095017024097328/ownership.xml","form_type":"4"}},{"id":1433708,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-14T20:07:30.000Z","date":"2024-08-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the \"Repriced Options\"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the \"Repricing\"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the \"Repriced Options\"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the \"Repricing\"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option vests in twenty-four equal monthly installments starting from November 15, 2022."}],"balance_after":0,"derivative":{"exercise_price":0.82,"expiration_date":"2032-11-14","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-24-097328","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000095017024097328/ownership.xml","form_type":"4"}},{"id":1433707,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-14T20:07:30.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the \"Repriced Options\"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the \"Repricing\"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the \"Repriced Options\"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the \"Repricing\"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests in twenty-four equal monthly installments starting from August 25, 2022."}],"balance_after":60000,"derivative":{"exercise_price":0.55,"expiration_date":"2032-08-24","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-24-097328","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000095017024097328/ownership.xml","form_type":"4"}},{"id":1433706,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-14T20:07:30.000Z","date":"2024-08-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the \"Repriced Options\"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the \"Repricing\"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the \"Repriced Options\"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the \"Repricing\"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests in twenty-four equal monthly installments starting from August 25, 2022."}],"balance_after":0,"derivative":{"exercise_price":1.71,"expiration_date":"2032-08-24","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-24-097328","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000095017024097328/ownership.xml","form_type":"4"}},{"id":1433705,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-14T20:07:30.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":127500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the \"Repriced Options\"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the \"Repricing\"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the \"Repriced Options\"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the \"Repricing\"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option vests over three years, with 1/3 of the shares vesting on December 23, 2022, and 1/36th of the shares vesting monthly thereafter."}],"balance_after":127500,"derivative":{"exercise_price":0.55,"expiration_date":"2032-02-13","underlying":"Common Stock","underlying_shares":127500},"source":{"system":"sec-edgar","filing":"0000950170-24-097328","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000095017024097328/ownership.xml","form_type":"4"}},{"id":1433704,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-14T20:07:30.000Z","date":"2024-08-12","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":127500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the \"Repriced Options\"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the \"Repricing\"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 12, 2024, the stockholders of the Issuer approved the repricing of certain outstanding options to purchase common stock (the \"Repriced Options\"), with the new exercise price being the closing price of the Issuer's common stock on the Nasdaq Capital Market on August 12, 2024, rounded up to the nearest penny (the \"Repricing\"). There is no change to the number of shares underlying the Repriced Options or the vesting schedule or expiration dates of the Repriced Options. The Repricing was approved by the Board of Directors of the Issuer on June 26, 2024, based on the recommendation of the Compensation Committee of the Board of Directors."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option vests over three years, with 1/3 of the shares vesting on December 23, 2022, and 1/36th of the shares vesting monthly thereafter."}],"balance_after":0,"derivative":{"exercise_price":6.26,"expiration_date":"2032-02-13","underlying":"Common Stock","underlying_shares":127500},"source":{"system":"sec-edgar","filing":"0000950170-24-097328","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000095017024097328/ownership.xml","form_type":"4"}},{"id":1499228,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-29T20:54:01.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":53254,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option grant was approved on March 7, 2024, subject to stockholder approval of an amendment to the Vincerx Pharma, Inc. 2020 Stock Incentive Plan. The stockholders approved the amendment on May 23, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-third (1/3) vests on March 7, 2025, with the remainder vesting in twenty-four equal monthly installments thereafter."}],"balance_after":200000,"derivative":{"exercise_price":7.38,"expiration_date":"2034-03-06","underlying":"Common Stock","underlying_shares":53254},"source":{"system":"sec-edgar","filing":"0000950170-24-066201","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000095017024066201/ownership.xml","form_type":"4"}},{"id":1586903,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-08T20:00:43.000Z","date":"2024-03-07","kind":"grant","planned":false,"acquired":true,"shares":146746,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third (1/3) vests on March 7, 2025, with the remainder vesting in twenty-four equal monthly installments thereafter."}],"balance_after":146746,"derivative":{"exercise_price":7.38,"expiration_date":"2034-03-06","underlying":"Common Stock","underlying_shares":146746},"source":{"system":"sec-edgar","filing":"0000950170-24-028861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000095017024028861/ownership.xml","form_type":"4"}},{"id":1810923,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-08-10T18:28:32.000Z","date":"2023-08-10","kind":"purchase","planned":false,"acquired":true,"shares":5400,"price":0.9569,"value":5167.26,"ownership":{"direct":false,"nature":"The Hamdy Family Trust dated 10/17/2015"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents actual price."}],"balance_after":96060,"source":{"system":"sec-edgar","filing":"0000950170-23-041517","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000095017023041517/ownership.xml","form_type":"4"}},{"id":1810922,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-08-10T18:28:32.000Z","date":"2023-08-09","kind":"purchase","planned":false,"acquired":true,"shares":16900,"price":0.9464,"value":15994.16,"ownership":{"direct":false,"nature":"I   The Hamdy Family Trust dated 10/17/2015"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average purchase price. Actual purchase prices ranged from $0.88 to $0.95 per share. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares purchased within the range indicated."}],"balance_after":90660,"source":{"system":"sec-edgar","filing":"0000950170-23-041517","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000095017023041517/ownership.xml","form_type":"4"}},{"id":2011110,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-16T16:05:17.000Z","date":"2023-02-15","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests in twenty-four equal monthly installments starting from February 15, 2023."}],"balance_after":90000,"derivative":{"exercise_price":1.17,"expiration_date":"2033-02-14","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0000899243-23-005242","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000089924323005242/doc4.xml","form_type":"4"}},{"id":2086566,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-14T21:22:15.000Z","date":"2022-12-14","kind":"purchase","acquired":true,"shares":35280,"price":0.8656,"value":30538.368,"ownership":{"direct":false,"nature":"The Hamdy Family Trust dated 10/7/2015"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average purchase price. Actual purchase prices ranged from $0.829 to $0.87 per share. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares purchased within the range indicated."}],"balance_after":73760,"source":{"system":"sec-edgar","filing":"0000899243-22-038529","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000089924322038529/doc4.xml","form_type":"4"}},{"id":2112314,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-11-17T16:06:34.000Z","date":"2022-11-15","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests in twenty-four equal monthly installments starting from November 15, 2022."}],"balance_after":60000,"derivative":{"exercise_price":0.817,"expiration_date":"2032-11-14","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000899243-22-036181","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000089924322036181/doc4.xml","form_type":"4"}},{"id":2171923,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-08-29T16:05:47.000Z","date":"2022-08-25","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests in twenty-four equal monthly installments starting from August 25, 2022."}],"balance_after":60000,"derivative":{"exercise_price":1.71,"expiration_date":"2032-08-24","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000899243-22-029970","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000089924322029970/doc4.xml","form_type":"4"}},{"id":2221257,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-06-27T19:20:13.000Z","date":"2022-06-23","kind":"purchase","acquired":true,"shares":24200,"price":1.4106,"value":34136.52,"ownership":{"direct":false,"nature":"The Hamdy Family Trust dated 10/7/2015"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents actual price."}],"balance_after":38480,"source":{"system":"sec-edgar","filing":"0000899243-22-024247","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000089924322024247/doc4.xml","form_type":"4"}},{"id":2392031,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-16T16:10:32.000Z","date":"2022-02-14","kind":"grant","acquired":true,"shares":127500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests over three years, with 1/3 of the shares vesting on December 23, 2022, and 1/36th of the shares vesting monthly thereafter."}],"balance_after":127500,"derivative":{"exercise_price":6.26,"expiration_date":"2032-02-13","underlying":"Common Stock","underlying_shares":127500},"source":{"system":"sec-edgar","filing":"0000899243-22-006631","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000089924322006631/doc4.xml","form_type":"4"}},{"id":2458677,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-27T16:28:05.000Z","date":"2021-12-22","kind":"purchase","acquired":true,"shares":6450,"price":10.0232,"value":64649.64,"ownership":{"direct":false,"nature":"The Hamdy Family Trust dated 10/7/2015"},"balance_after":14280,"source":{"system":"sec-edgar","filing":"0000899243-21-049763","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000089924321049763/doc4.xml","form_type":"4"}},{"id":2650295,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-06-30T19:02:45.000Z","date":"2021-06-29","kind":"purchase","acquired":true,"shares":7830,"price":12.77,"value":99989.1,"ownership":{"direct":false,"nature":"The Hamdy Family Trust dated 10/7/2015"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average purchase price. Actual purchase prices ranged from $12.59 to $12.77 per share. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares purchased within the range indicated."}],"balance_after":7830,"source":{"system":"sec-edgar","filing":"0000899243-21-026820","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000089924321026820/doc4.xml","form_type":"4"}},{"id":2931535,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":56629,"kind":"person","name":"Hamdy Ahmed MD","position":1,"cik":"0001458506","reported_name":"Hamdy Ahmed MD","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-12-28T21:41:49.000Z","date":"2020-12-23","kind":"grant","acquired":true,"shares":1618199,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received pursuant to the Merger Agreement, dated as of September 25, 2020, by and among LifeSci Acquisition Corp. (\"LifeSci\"), Vincera Pharma, Inc. (\"Legacy Vincera\") and LifeSci Acquisition Merger Sub, Inc., a wholly-owned subsidiary of LifeSci (\"Merger Sub\"), pursuant to which Merger Sub merged with and into Legacy Vincera, with Legacy Vincera surviving the merger as a wholly-owned subsidiary of LifeSci (which subsequently changed its name to \"Vincera Pharma, Inc.\")."}],"balance_after":1618199,"source":{"system":"sec-edgar","filing":"0000899243-20-035408","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000089924320035408/doc4.xml","form_type":"4"}}]}